The demographics of the 12 patients developing low serum IgM levels following rituximab are shown in Supplementary Table 1 (available on the Arthritis Care & Research web site at http://onlinelibrary.wiley.com/doi/10.1002/acr.22993/abstract). This evidence concerns the gene CD40LG and arthritic joint disease.